The Global Triptorelin Market, by Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty), By End User (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), was valued US$ 426.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over the forecast period (2018 - 2026). Triptorelin is agonist analogue of natural gonadotropin-releasing hormone (GnRH). Triptorelin act as GnRH agonists, by reducing the level of sex hormones such as testosterone in the body. Reducing testosterone levels helps to slow progression of prostate cancer in addition to reducing the bone pain, urinary problems and other symptoms of prostate cancer. Moreover, key players in the triptorelin market are engaged in various activities to expand their geographical presence. For instance, in December 2015, United Laboratories Inc. and Debiopharm International SA made and exclusive agreement for the distribution and commercialization of Pamorelin: 1, 3, and 6-month formulations in the Philippines, for the treatment of locally advanced and metastatic hormone-dependent prostate cancer and as adjuvant to radiotherapy in high-risk localized and locally advanced prostate cancer, and for the treatment of endometriosis (1- and 3-month formulations only).
Browse 26 Market Data Tables and 21 Figures spread through 152 Pages and in-depth TOC on "Triptorelin Market, by Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty), By End User (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) - Global Forecast to 2026"
To know the latest trends and insights related to triptorelin market, click the link below:
Furthermore, key players are engaged in launching triptorelin-based product in market along with gaining regulatory approval for the same. Debiopharm Group are continuously launching triptorelin product portfolio in various geographical locations. For instance, in September 2014, Actavis Specialty Pharmaceuticals Co. (operated as a subsidiary of Teva Pharmaceutical Industries Ltd.) and Debiopharm Group announced launch of Trelstar (triptorelin pamoate) in six-month dosing option (22.5 mg) in Canada. Trelstar is indicated for the palliative treatment of hormone dependent advanced prostate cancer in Canada. Moreover, new dosing option eases the burden of patients, with decreased number of injections and thereby low incidence of injection site pain, while providing long-term sustained testosterone suppression. In December 2012, Dr. Reddy’s Laboratories Ltd. launched Debiopharm’s Pamorelin LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. According to the agreement, Dr. Reddy’s Laboratories acquired exclusive marketing and sales rights for Pamorelin LA Depot in India. Dr. Reddy’s Laboratories will deliver Pamorelin LA primarily to urologists and oncologists across India. In May 2014, Orient EuroPharma Co., Ltd. - a pharmaceutical company engaged in the marketing and commercialization of pharmaceutical products in Malaysia, Hong Kong, Singapore, and Philippines and Debiopharm Group – entered into distribution agreement for the commercialization and promotion of Pamorelin in South East Asia. Under the agreement, Orient EuroPharma acquired exclusive marketing and sales rights for Pamorelin in Singapore, their first launch territory.
Key takeaways of the Triptorelin Market:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.